Do you want to tell us a little bit more about UMC's role in the program overall? Because we've said we help member countries develop their pharmacovigilant systems, but what does that support look like in practice for someone who isn't familiar with UMC's offering?

Well, in our role as a WHO collaborating centre to support pharmacovigilance activities, in a nutshell, we provide technical, operational and scientific support to the regulatory authorities or ministries of health that are members of the programme.

And we do that in several different ways.

For example, we offer VigiFlow as the national pharmacovigilance database for the countries that want to use it.

The usage of VigiFlow is not mandatory.

But we offer it for free for those regulatory authorities or immunization programs that don't have a system like that and want to have a top of the line system that allows you to collect data electronically, that it's aligned with the current ICH and WHO recommendations.

So we have that as a technological solution to collect reports.

So as it evolves, how should the program evolve with it? And what role will UMC play, do you think?